Search | Clinical Trials Finder

Conditions: Meniere's Disease
Interventions: SPI-1005; Drug
Lead sponsor: Sound Pharmaceuticals, Incorporated; Industry
Eligibility: 19 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 5
States / cities: Los Angeles, California • New York, New York • Charleston, South Carolina + 1 more

Conditions: Postpartum Hemorrhage
Interventions: Tranexamic Acid; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Myelofibrosis
Interventions: Nusivertib, Ruxolitinib, Momelotinib; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 32
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 25 more

Conditions: Advanced Solid Tumors
Interventions: axitinib, crizotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 15
States / cities: Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 5 more

Conditions: Breast Cancer, Advanced Solid Tumor
Interventions: BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 6
States / cities: Birmingham, Alabama • New Haven, Connecticut • St Louis, Missouri + 3 more

Conditions: Dyslipidemias, Non-Alcoholic Fatty Liver Disease
Interventions: LY3885125, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Anemia
Interventions: COR-001, Placebo; Drug · Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 12
States / cities: Northridge, California • Hollywood, Florida • Tampa, Florida + 9 more

Conditions: Uncontrolled Gout, Chronic Gout
Interventions: Pegloticase, Methotrexate (MTX); Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Anchorage, Alaska • Glendale, Arizona • San Leandro, California + 9 more

Conditions: Multiple Myeloma
Interventions: AZD0120; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Phoenix, Arizona • Duarte, California • Denver, Colorado + 10 more

Conditions: Mucopolysaccharidosis IIIB
Interventions: SBC-103; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Pittsburgh, Pennsylvania

Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
Interventions: SNS-101 (anti-VISTA), Cemiplimab; Drug
Lead sponsor: Sensei Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more

Conditions: Healthy Volunteers, Hepatitis C Virus
Interventions: RO5024048; Drug
Lead sponsor: Pharmasset; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 7
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Ezogabine, Placebo; Drug
Lead sponsor: Brian Wainger; Other
Eligibility: 18 Years to 80 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 8 more

Conditions: Healthy Subjects
Interventions: LX4211 400 mg, canagliflozin 300 mg, LX4211 Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
Interventions: Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b; Biological
Lead sponsor: AC Immune SA; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 13
States / cities: Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more

Conditions: Cystic Fibrosis
Interventions: VX-809, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 18
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more

Conditions: Hyperphosphatemia
Interventions: DS-2330b PIB, Placebo, Sevelamer, DS-2330b Tablet; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Type 2 Diabetes Mellitus
Interventions: LGD-6972, Placebo (Captisol®); Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Infections
Interventions: Indinavir sulfate, Delavirdine mesylate, Zidovudine; Drug
Lead sponsor: Pharmacia and Upjohn; Industry
Eligibility: 14 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • New York, New York + 3 more

Conditions: Pompe Disease, Glycogen Storage Disease Type II (GSD II), Acid Maltase Deficiency
Interventions: GZ402666; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 7
States / cities: Phoenix, Arizona • Jacksonville, Florida • Kansas City, Kansas + 4 more

Conditions: Methamphetamine Metabolism, CYP2D6 Genotype
Interventions: A single oral 5 mg of duterium labeled methamphetamine; Drug
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cancer, Neoplasms
Interventions: GSK2820151; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Detroit, Michigan • Nashville, Tennessee

Conditions: HIV Infection
Interventions: Griffithsin Gel, Placebo Gel; Drug
Lead sponsor: Population Council; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: Fazisiran Injection, Placebo; Drug · Other
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 16
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 13 more

Search by objective public record fields.

Study to Evaluate SPI-1005 in Adults With Meniere's Disease

Prevention of Postpartum Hemorrhage With Tranexamic Acid

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001

A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation

DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.

The Impact of Genetic Variation in CYP2D6 on the Pharmacokinetics and Pharmacodynamics of Methamphetamine

Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors

Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women

Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)